{"id":"epirubicin-with-a-taxane","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Neutropenia"},{"rate":"20-50","effect":"Anemia"},{"rate":"10-30","effect":"Thrombocytopenia"},{"rate":"30-60","effect":"Nausea and vomiting"},{"rate":"40-80","effect":"Alopecia"},{"rate":"20-40","effect":"Peripheral neuropathy"},{"rate":"1-5","effect":"Cardiotoxicity"},{"rate":"10-30","effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL417","moleculeType":"Small molecule","molecularWeight":"543.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epirubicin is an anthracycline that intercalates into DNA and generates reactive oxygen species, causing DNA damage and cell death. Taxanes (paclitaxel or docetaxel) stabilize microtubules and prevent their disassembly, disrupting mitotic spindle formation. The combination leverages complementary mechanisms to enhance cytotoxic effects against cancer cells.","oneSentence":"Epirubicin and taxanes work together as chemotherapy agents that damage cancer cell DNA and disrupt microtubule formation, respectively, to kill rapidly dividing tumor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:12.833Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (early-stage and metastatic)"},{"name":"Gastric cancer"},{"name":"Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT00066443","phase":"PHASE1, PHASE2","title":"Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2003-11-03","conditions":"Breast Cancer","enrollment":93},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT07441460","phase":"PHASE3","title":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2026-03-07","conditions":"Resectable HER2-positive Breast Cancer","enrollment":1800},{"nctId":"NCT06829199","phase":"PHASE2","title":"A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-26","conditions":"Early Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT06291064","phase":"PHASE2","title":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Triple Negative Breast Cancer","enrollment":85},{"nctId":"NCT06009627","phase":"PHASE2, PHASE3","title":"Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-11","conditions":"Breast Cancer","enrollment":119},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT03879577","phase":"PHASE2","title":"Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-11-25","conditions":"Breast Cancer, Breast Cancer Female, HER2-positive Breast Cancer","enrollment":53},{"nctId":"NCT06513364","phase":"PHASE1","title":"Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"Beijing Wehand-Bio Pharmaceutical Co., Ltd","startDate":"2024-09-10","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT04770272","phase":"PHASE2","title":"Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy","status":"TERMINATED","sponsor":"Palleos Healthcare GmbH","startDate":"2021-03-01","conditions":"Triple-negative Breast Cancer","enrollment":442},{"nctId":"NCT04290793","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2020-03-01","conditions":"Breast Cancer","enrollment":113},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT07317778","phase":"PHASE2","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-15","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer","enrollment":249},{"nctId":"NCT06112379","phase":"PHASE3","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-14","conditions":"Breast Cancer","enrollment":1902},{"nctId":"NCT06107673","phase":"PHASE2","title":"Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2023-09-30","conditions":"Breast Cancer","enrollment":144},{"nctId":"NCT07254858","phase":"PHASE2","title":"Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-12","conditions":"HR+/HER2- Breast Cancer","enrollment":302},{"nctId":"NCT01358877","phase":"PHASE3","title":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-08","conditions":"Breast Cancer","enrollment":4804},{"nctId":"NCT07016399","phase":"PHASE2","title":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","status":"RECRUITING","sponsor":"Vandana Abramson","startDate":"2025-09-09","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma","enrollment":51},{"nctId":"NCT03036488","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-07","conditions":"Triple Negative Breast Neoplasms","enrollment":1174},{"nctId":"NCT04335669","phase":"PHASE3","title":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lund University Hospital","startDate":"2019-12-20","conditions":"Breast Cancer, Triple Negative Breast Neoplasms","enrollment":325},{"nctId":"NCT03515798","phase":"PHASE2","title":"Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Paoli-Calmettes","startDate":"2018-08-29","conditions":"Inflammatory Breast Cancer","enrollment":52},{"nctId":"NCT05900206","phase":"PHASE2","title":"Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2023-10-26","conditions":"Breast Cancer","enrollment":370},{"nctId":"NCT05862064","phase":"PHASE3","title":"A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":606},{"nctId":"NCT03725059","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":1240},{"nctId":"NCT01354522","phase":"PHASE3","title":"TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2011-05","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT04296175","phase":"PHASE3","title":"Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2020-03-05","conditions":"Triple-negative Breast Cancer","enrollment":808},{"nctId":"NCT05024734","phase":"PHASE2","title":"Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids","status":"RECRUITING","sponsor":"Roland Seiler-Blarer","startDate":"2023-02-21","conditions":"Bladder Cancer, Non-muscle Invasive","enrollment":34},{"nctId":"NCT01924819","phase":"PHASE2, PHASE3","title":"Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":574},{"nctId":"NCT06795503","phase":"PHASE3","title":"Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-02","conditions":"Triple-negative Breast Cancer","enrollment":1462},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT03356860","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.","status":"COMPLETED","sponsor":"Grand Hôpital de Charleroi","startDate":"2017-04-13","conditions":"Breast Cancer, Triple Negative Breast Cancer, Luminal B","enrollment":57},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT03013504","phase":"PHASE3","title":"A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients","status":"COMPLETED","sponsor":"Prestige Biopharma Limited","startDate":"2018-02-19","conditions":"HER2 Positive Breast Cancer","enrollment":503},{"nctId":"NCT03355157","phase":"PHASE4","title":"A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2018-03-01","conditions":"Metastatic Breast Cancer","enrollment":130},{"nctId":"NCT03498716","phase":"PHASE3","title":"A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2018-08-02","conditions":"Triple Negative Breast Cancer","enrollment":2199},{"nctId":"NCT06102252","phase":"NA","title":"Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2024-08-15","conditions":"Endometrial Carcinoma","enrollment":80},{"nctId":"NCT00433420","phase":"PHASE3","title":"Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"2003-04","conditions":"Breast Cancer","enrollment":2000},{"nctId":"NCT06404463","phase":"PHASE2","title":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-05-06","conditions":"Early Breast Cancer, Neoadjuvant Therapy, HR+HER2- Breast Cancer","enrollment":76},{"nctId":"NCT03272477","phase":"PHASE2","title":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Palleos Healthcare GmbH","startDate":"2017-10-05","conditions":"Breast Neoplasms","enrollment":257},{"nctId":"NCT06371807","phase":"PHASE2","title":"Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab","status":"NOT_YET_RECRUITING","sponsor":"Fundacao Champalimaud","startDate":"2024-07","conditions":"Early Breast Cancer, Triple Negative Breast Cancer","enrollment":20},{"nctId":"NCT02620280","phase":"PHASE3","title":"Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1","status":"COMPLETED","sponsor":"Fondazione Michelangelo","startDate":"2016-04","conditions":"Invasive Ductal Breast Carcinoma","enrollment":278},{"nctId":"NCT06227065","phase":"PHASE2","title":"Precise Neoadjuvant Chemoresection of Low Grade NMIBC","status":"NOT_YET_RECRUITING","sponsor":"University of Bern","startDate":"2024-10","conditions":"Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low-risk","enrollment":28},{"nctId":"NCT03609047","phase":"PHASE2","title":"Adjuvant Palbociclib in Elderly Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2019-06-14","conditions":"Breast Cancer Stage II, Breast Cancer Stage III","enrollment":366},{"nctId":"NCT05978648","phase":"PHASE2","title":"Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy","status":"RECRUITING","sponsor":"wang shusen","startDate":"2023-09-20","conditions":"Breast Neoplasms","enrollment":116},{"nctId":"NCT00525759","phase":"PHASE2","title":"Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2007-07","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT04172259","phase":"PHASE2","title":"ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-01-10","conditions":"Breast Cancer, Neoadjuvant Chemotherapy","enrollment":156},{"nctId":"NCT05569811","phase":"PHASE2","title":"NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2022-11-25","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT05985187","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-10-20","conditions":"HER2-positive Breast Cancer","enrollment":412},{"nctId":"NCT05883852","phase":"PHASE3","title":"EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-07","conditions":"HER2 Positive Early Breast Cancer","enrollment":1406},{"nctId":"NCT05901428","phase":"PHASE3","title":"TCb vs EC-T in High Risk ER+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer","enrollment":1736},{"nctId":"NCT05128617","phase":"","title":"Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study","status":"COMPLETED","sponsor":"Institut de cancérologie Strasbourg Europe","startDate":"2021-11-04","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT02586025","phase":"PHASE3","title":"Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-14","conditions":"Breast Cancer","enrollment":329},{"nctId":"NCT00432172","phase":"PHASE2","title":"Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2007-04-24","conditions":"Breast Cancer","enrollment":189},{"nctId":"NCT00841828","phase":"PHASE2","title":"Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2009-02","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT00129935","phase":"PHASE3","title":"EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2004-02","conditions":"Breast Cancer","enrollment":1384},{"nctId":"NCT02315196","phase":"PHASE2","title":"Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2015-02-25","conditions":"Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer","enrollment":62},{"nctId":"NCT02067416","phase":"PHASE2","title":"PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer","status":"WITHDRAWN","sponsor":"Jenny C. Chang, MD","startDate":"2012-07","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT05681728","phase":"PHASE2","title":"A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-02-01","conditions":"Breast Cancer","enrollment":26},{"nctId":"NCT00773695","phase":"PHASE2","title":"A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11-07","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT05656079","phase":"NA","title":"To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Pudong Hospital","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT05636644","phase":"","title":"Neoadjuvant Effect of Albumin Binding Paclitaxel Compared With Common Paclitaxel in Breast Cancer：an Observational Single Center Study of Clinical Efficacy in Adjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Mei Zhang","startDate":"2022-11-04","conditions":"Breast Cancer","enrollment":112},{"nctId":"NCT01779050","phase":"PHASE2","title":"Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2013-12-19","conditions":"Breast Neoplasms","enrollment":7},{"nctId":"NCT03154749","phase":"PHASE2","title":"DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2016-09-01","conditions":"Triple-Negative Breast Cancer","enrollment":93},{"nctId":"NCT05483439","phase":"PHASE2","title":"A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2021-10-20","conditions":"Stage II-III Breast Cancer","enrollment":100},{"nctId":"NCT05420467","phase":"PHASE4","title":"A Study for the Adjuvant Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-10","conditions":"Breast Cancer","enrollment":2413},{"nctId":"NCT01966471","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-31","conditions":"Breast Cancer","enrollment":1846},{"nctId":"NCT05400993","phase":"PHASE2","title":"Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2022-05-23","conditions":"Breast Cancer","enrollment":59},{"nctId":"NCT00248703","phase":"PHASE2","title":"Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2003-10","conditions":"Breast Cancer","enrollment":1128},{"nctId":"NCT05251766","phase":"PHASE1","title":"Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer","status":"UNKNOWN","sponsor":"Xuli Meng","startDate":"2022-04-20","conditions":"Breast Cancer, Chemotherapy Effect","enrollment":30},{"nctId":"NCT04771871","phase":"PHASE2","title":"MicroRNA Profiles in Triple Negative Breast Cancer","status":"UNKNOWN","sponsor":"University College Hospital, Ibadan","startDate":"2021-11-29","conditions":"Triple Negative Breast Cancer","enrollment":42},{"nctId":"NCT03556358","phase":"PHASE3","title":"Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer","status":"COMPLETED","sponsor":"Tanvex BioPharma USA, Inc.","startDate":"2018-06-28","conditions":"Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer","enrollment":809},{"nctId":"NCT05131893","phase":"","title":"Neoadjuvant Treatment of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Oncology, Hungary","startDate":"2022-03","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT02468739","phase":"PHASE3","title":"Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-05","conditions":"Breast Cancer","enrollment":206},{"nctId":"NCT00464646","phase":"PHASE2","title":"Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2007-05","conditions":"Breast Cancer","enrollment":105},{"nctId":"NCT03894007","phase":"PHASE2","title":"Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer","status":"TERMINATED","sponsor":"Renske Altena","startDate":"2019-05-23","conditions":"Early-stage Breast Cancer, HER2-positive Breast Cancer","enrollment":6},{"nctId":"NCT01593020","phase":"PHASE2","title":"Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-08-03","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT02132949","phase":"PHASE2","title":"A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-07-14","conditions":"Breast Cancer","enrollment":401},{"nctId":"NCT04576143","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-09-20","conditions":"HER2-negative Breast Cancer, Neoadjuvant Chemotherapy","enrollment":260},{"nctId":"NCT04136782","phase":"PHASE4","title":"Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Shengjing Hospital","startDate":"2021-07-19","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT04717531","phase":"PHASE2","title":"Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-06-03","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT01220128","phase":"PHASE2","title":"Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-04-11","conditions":"Neoplasms, Breast","enrollment":66},{"nctId":"NCT03983538","phase":"","title":"Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer","status":"COMPLETED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2015-06-02","conditions":"Breast Cancer","enrollment":10},{"nctId":"NCT03289819","phase":"PHASE2","title":"Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC","status":"COMPLETED","sponsor":"Institut fuer Frauengesundheit","startDate":"2018-03-23","conditions":"Malignant Neoplasm of Breast","enrollment":53},{"nctId":"NCT02128243","phase":"PHASE2","title":"Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-09","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma","enrollment":242},{"nctId":"NCT02324088","phase":"PHASE3","title":"Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2000-10","conditions":"Inflammatory Breast Cancer","enrollment":174},{"nctId":"NCT02685059","phase":"PHASE2","title":"Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2016-06","conditions":"Breast Cancer","enrollment":174},{"nctId":"NCT03025477","phase":"PHASE2","title":"Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer","status":"RECRUITING","sponsor":"Groupe Hospitalier Diaconesses Croix Saint-Simon","startDate":"2016-10","conditions":"Ovarian Cancer, Epithelial","enrollment":84},{"nctId":"NCT01690702","phase":"PHASE3","title":"Study of Nab-Paclitaxel in High Risk Early Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2012-09","conditions":"Breast Cancer","enrollment":2886},{"nctId":"NCT03144947","phase":"PHASE2","title":"Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients","status":"UNKNOWN","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2016-11-29","conditions":"Cancer, Breast","enrollment":65},{"nctId":"NCT00014222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2000-12-04","conditions":"Breast Cancer","enrollment":2104},{"nctId":"NCT00625898","phase":"PHASE3","title":"BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab","status":"TERMINATED","sponsor":"NSABP Foundation Inc","startDate":"2008-04","conditions":"Breast Cancer","enrollment":3509},{"nctId":"NCT02568839","phase":"PHASE2, PHASE3","title":"Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Hatschek","startDate":"2014-11","conditions":"Early-Stage Breast Carcinoma, HER-2 Positive Breast Cancer","enrollment":202},{"nctId":"NCT01583426","phase":"PHASE3","title":"Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2012-07","conditions":"Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS","enrollment":1229},{"nctId":"NCT04499118","phase":"PHASE2","title":"AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer","status":"UNKNOWN","sponsor":"Sichuan Provincial People's Hospital","startDate":"2020-08","conditions":"HER2-negative Breast Cancer","enrollment":100},{"nctId":"NCT04474951","phase":"NA","title":"Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies","status":"UNKNOWN","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2019-06-20","conditions":"Breast Cancer, Gynecologic Cancer","enrollment":60},{"nctId":"NCT04437160","phase":"PHASE2","title":"Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences","startDate":"2020-02-01","conditions":"Triple Negative Breast Cancer","enrollment":286},{"nctId":"NCT01216111","phase":"PHASE3","title":"Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2011-01-01","conditions":"Triple Negative Breast Cancer","enrollment":647},{"nctId":"NCT00002866","phase":"PHASE1","title":"Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1996-08-12","conditions":"Breast Cancer, Neutropenia","enrollment":50},{"nctId":"NCT02879513","phase":"PHASE3","title":"Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2014-01","conditions":"Invasive Ductal Breast Cancer, Tubular Breast Cancer, Mucinous Breast Cancer","enrollment":290}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":42,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Epirubicin, ellence,"],"phase":"phase_3","status":"active","brandName":"Epirubicin with a Taxane","genericName":"Epirubicin with a Taxane","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epirubicin and taxanes work together as chemotherapy agents that damage cancer cell DNA and disrupt microtubule formation, respectively, to kill rapidly dividing tumor cells. Used for Breast cancer (early-stage and metastatic), Gastric cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}